vs
劳瑞德教育集团（LAUR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是劳瑞德教育集团的1.4倍（$772.1M vs $541.4M），劳瑞德教育集团净利率更高（31.7% vs 12.7%，领先18.9%），劳瑞德教育集团同比增速更快（27.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $26.4M），过去两年劳瑞德教育集团的营收复合增速更高（40.2% vs 9.0%）
劳瑞德教育集团是总部位于美国佛罗里达州迈阿密的教育运营企业，旗下拥有并运营劳瑞德国际大学体系，在墨西哥、秘鲁设有多个校区，目前于纳斯达克证券交易所公开上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LAUR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$541.4M
营收增速更快
LAUR
高出22.0%
5.9%
净利率更高
LAUR
高出18.9%
12.7%
自由现金流更多
RVTY
多$135.4M
$26.4M
两年增速更快
LAUR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $541.4M | $772.1M |
| 净利润 | $171.6M | $98.4M |
| 毛利率 | 35.8% | — |
| 营业利润率 | 33.2% | 14.5% |
| 净利率 | 31.7% | 12.7% |
| 营收同比 | 27.9% | 5.9% |
| 净利润同比 | 83.2% | 3.9% |
| 每股收益（稀释后） | $1.14 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LAURRVTY
| Q4 25 | $541.4M | $772.1M | ||
| Q3 25 | $400.2M | $698.9M | ||
| Q2 25 | $524.2M | $720.3M | ||
| Q1 25 | $236.2M | $664.8M | ||
| Q4 24 | $423.4M | $729.4M | ||
| Q3 24 | $368.6M | $684.0M | ||
| Q2 24 | $499.2M | $691.7M | ||
| Q1 24 | $275.4M | $649.9M |
净利润LAURRVTY
| Q4 25 | $171.6M | $98.4M | ||
| Q3 25 | $34.5M | $46.7M | ||
| Q2 25 | $95.1M | $53.9M | ||
| Q1 25 | $-19.5M | $42.2M | ||
| Q4 24 | $93.6M | $94.6M | ||
| Q3 24 | $85.5M | $94.4M | ||
| Q2 24 | $128.1M | $55.4M | ||
| Q1 24 | $-10.8M | $26.0M |
毛利率LAURRVTY
| Q4 25 | 35.8% | — | ||
| Q3 25 | 20.9% | 53.6% | ||
| Q2 25 | 39.5% | 54.5% | ||
| Q1 25 | -0.9% | 56.5% | ||
| Q4 24 | 32.0% | — | ||
| Q3 24 | 22.4% | 56.3% | ||
| Q2 24 | 36.1% | 55.7% | ||
| Q1 24 | 7.8% | 54.6% |
营业利润率LAURRVTY
| Q4 25 | 33.2% | 14.5% | ||
| Q3 25 | 17.9% | 11.7% | ||
| Q2 25 | 36.9% | 12.6% | ||
| Q1 25 | -5.6% | 10.9% | ||
| Q4 24 | 29.3% | 16.3% | ||
| Q3 24 | 19.5% | 14.3% | ||
| Q2 24 | 33.4% | 12.4% | ||
| Q1 24 | 4.0% | 6.8% |
净利率LAURRVTY
| Q4 25 | 31.7% | 12.7% | ||
| Q3 25 | 8.6% | 6.7% | ||
| Q2 25 | 18.1% | 7.5% | ||
| Q1 25 | -8.3% | 6.4% | ||
| Q4 24 | 22.1% | 13.0% | ||
| Q3 24 | 23.2% | 13.8% | ||
| Q2 24 | 25.7% | 8.0% | ||
| Q1 24 | -3.9% | 4.0% |
每股收益（稀释后）LAURRVTY
| Q4 25 | $1.14 | $0.86 | ||
| Q3 25 | $0.23 | $0.40 | ||
| Q2 25 | $0.65 | $0.46 | ||
| Q1 25 | $-0.13 | $0.35 | ||
| Q4 24 | $0.60 | $0.77 | ||
| Q3 24 | $0.56 | $0.77 | ||
| Q2 24 | $0.83 | $0.45 | ||
| Q1 24 | $-0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.7M | $919.9M |
| 总债务越低越好 | $73.1M | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $2.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.06× | — |
8季度趋势，按日历期对齐
现金及短期投资LAURRVTY
| Q4 25 | $146.7M | $919.9M | ||
| Q3 25 | $241.0M | $931.4M | ||
| Q2 25 | $135.3M | $991.8M | ||
| Q1 25 | $109.8M | $1.1B | ||
| Q4 24 | $91.3M | $1.2B | ||
| Q3 24 | $134.4M | $1.2B | ||
| Q2 24 | $128.8M | $2.0B | ||
| Q1 24 | $126.2M | $1.7B |
总债务LAURRVTY
| Q4 25 | $73.1M | — | ||
| Q3 25 | $70.6M | — | ||
| Q2 25 | $78.1M | — | ||
| Q1 25 | $91.0M | — | ||
| Q4 24 | $59.0M | — | ||
| Q3 24 | $129.8M | — | ||
| Q2 24 | $203.0M | — | ||
| Q1 24 | $176.6M | — |
股东权益LAURRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $908.5M | $7.6B | ||
| Q4 24 | $959.5M | $7.7B | ||
| Q3 24 | $897.7M | $7.9B | ||
| Q2 24 | $918.0M | $7.9B | ||
| Q1 24 | $933.6M | $7.8B |
总资产LAURRVTY
| Q4 25 | $2.2B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.0B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $1.9B | $12.4B | ||
| Q3 24 | $1.9B | $12.8B | ||
| Q2 24 | $2.1B | $13.4B | ||
| Q1 24 | $2.2B | $13.4B |
负债/权益比LAURRVTY
| Q4 25 | 0.06× | — | ||
| Q3 25 | 0.06× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.10× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 4.9% | 21.0% |
| 资本支出强度资本支出/营收 | 12.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.54× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $263.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LAURRVTY
| Q4 25 | $93.4M | $182.0M | ||
| Q3 25 | $141.0M | $138.5M | ||
| Q2 25 | $74.1M | $134.3M | ||
| Q1 25 | $57.8M | $128.2M | ||
| Q4 24 | $40.7M | $174.2M | ||
| Q3 24 | $118.7M | $147.9M | ||
| Q2 24 | $40.2M | $158.6M | ||
| Q1 24 | $33.2M | $147.6M |
自由现金流LAURRVTY
| Q4 25 | $26.4M | $161.8M | ||
| Q3 25 | $122.8M | $120.0M | ||
| Q2 25 | $60.8M | $115.5M | ||
| Q1 25 | $53.2M | $112.2M | ||
| Q4 24 | $3.4M | $149.8M | ||
| Q3 24 | $110.7M | $125.6M | ||
| Q2 24 | $29.5M | $136.6M | ||
| Q1 24 | $17.3M | $129.7M |
自由现金流率LAURRVTY
| Q4 25 | 4.9% | 21.0% | ||
| Q3 25 | 30.7% | 17.2% | ||
| Q2 25 | 11.6% | 16.0% | ||
| Q1 25 | 22.5% | 16.9% | ||
| Q4 24 | 0.8% | 20.5% | ||
| Q3 24 | 30.0% | 18.4% | ||
| Q2 24 | 5.9% | 19.7% | ||
| Q1 24 | 6.3% | 20.0% |
资本支出强度LAURRVTY
| Q4 25 | 12.4% | 2.6% | ||
| Q3 25 | 4.5% | 2.6% | ||
| Q2 25 | 2.5% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 8.8% | 3.4% | ||
| Q3 24 | 2.2% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 5.8% | 2.7% |
现金转化率LAURRVTY
| Q4 25 | 0.54× | 1.85× | ||
| Q3 25 | 4.09× | 2.97× | ||
| Q2 25 | 0.78× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 0.43× | 1.84× | ||
| Q3 24 | 1.39× | 1.57× | ||
| Q2 24 | 0.31× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAUR
| Mexico Segment | $275.9M | 51% |
| Peru Segment | $265.5M | 49% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
